INS and type 1 diabetes mellitus: A recently published real‐world, secondary data analysis of off‐label use of SGLT‐2is as an adjunct therapy to insulin in T1DM in the United States from 2013 to 2018 revealed a real‐world DKA incidence in patients with T1DM of around 7.3 (5.81‐9.08) per 100 patient‐years.38